作者
Min-Hee Oh, Im-Hong Sun, Liang Zhao, Robert D Leone, Im-Meng Sun, Wei Xu, Samuel L Collins, Ada J Tam, Richard L Blosser, Chirag H Patel, Judson M Englert, Matthew L Arwood, Jiayu Wen, Yee Chan-Li, Lukáš Tenora, Pavel Majer, Rana Rais, Barbara S Slusher, Maureen R Horton, Jonathan D Powell
发表日期
2020/7/1
期刊
The Journal of clinical investigation
卷号
130
期号
7
页码范围
3865-3884
出版商
American Society for Clinical Investigation
简介
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited …
引用总数
学术搜索中的文章